HS
CPRX

HighVista Strategies’s Catalyst Pharmaceutical CPRX Stock Holding History

HighVista Strategies’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,800
Closed -$73K – 122
2020
Q2 		$73K Hold
15,800
– – 0.06% 85
2020
Q1 		$61K Hold
15,800
– – 0.06% 37
2019
Q4 		$59K Buy
+15,800
New +$73.9K 0.04% 117

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

HighVista Strategies's CPRX Position: Q3 2020 in Review

HighVista Strategies sold out of Catalyst Pharmaceutical (CPRX) in Q3 2020, closing a stake of 15,800 shares — an estimated $73K sold.

HighVista Strategies first reported a position in CPRX in Q4 2019 and held it in 3 quarters. The position peaked at $73K in Q2 2020. 142 funds tracked by Wall St. Rank hold CPRX as of Q3 2020.

  • HighVista Strategies reported no remaining Catalyst Pharmaceutical position as of Q3 2020 after selling out during the quarter.
  • HighVista Strategies sold 15,800 Catalyst Pharmaceutical shares in Q3 2020, an estimated $73K.
  • HighVista Strategies first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 3 quarters.
  • HighVista Strategies's Catalyst Pharmaceutical position peaked at $73K in Q2 2020.
  • 142 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2020.

Based on HighVista Strategies's 13F filing for Q3 2020, filed 16 Nov 2020.